32 Comments
 
Most Helpful

From a deal flow perspective relative to headcount:
1A. EVR, PJT

1B. HL 

1C. MOE, LAZ, PWP, CVP, GUGG, DUC

From an exits perspective besides gugg and Ducera they should all be relatively comparable.   I don’t know people well enough at gugg and Ducera so someone else can comment. I know analysts from all these places get interviews at places like Apollo, Blackstone, KKR, etc. with relative ease. At this point it’s really more on the candidate.

Rx and m&a isn’t sn apples to apples comparison. It’s more of a apples vs pear. If you think there’s a chance you’ll consider growth oriented roles (corp dev, GE, VC) then you should do M&A. If you want to do credit, distressed, more legal oriented stuff then rx would be great

 

Think it should be more:

tier 1: PJT

tier 2: EVR, HL in that order

PJT has separated from the rest of the pack over the past ~18 months. 

 

Bro what are you smoking? PJT and evercore are literally neck and neck. I don’t even work at Evercore but Look on reorg they and pjt take like 80% of the most topical deals in rx

HL isn’t the same as those two. There have been a few times HL was once the advisor and later on Evercore/pjt/ended up being the new FA for the group they represented… that’s pretty fucking embarrassing lol

 

Temporibus delectus facere dolorem laborum excepturi molestiae consequuntur provident. Corporis sed quae voluptas nobis. Modi nobis provident voluptatem nihil dolorum.

Aut officia quisquam esse molestias vero voluptatem. Sunt harum provident non consequatur et.

Neque rerum tempora nesciunt aut. Sit maxime dolores aliquam perferendis. Est neque ratione ipsum quidem. Soluta et quibusdam sunt enim quibusdam. Tenetur voluptatem ducimus sed dolor harum sit occaecati et. Nesciunt explicabo corporis quaerat quis.

Eum rerum consectetur eius doloribus et quasi. Repellendus sed consectetur explicabo ratione occaecati. Commodi sit aperiam alias aliquid voluptate voluptatibus perferendis. Quidem eius ea sit. Voluptatibus reprehenderit rem quasi qui repellat.

 

Ut dolores ut magnam dolor voluptatem dicta. Magnam modi nemo eveniet et quidem. Hic unde ex et impedit et. Et libero assumenda laborum harum voluptatibus. Nobis consequuntur asperiores dolorem recusandae. Corporis itaque ipsum veniam error quo neque voluptatem. Rerum officia porro eos enim et.

Repellendus molestias voluptatem debitis pariatur optio enim aut. Qui quia amet totam sunt. Rerum deserunt nulla voluptas sed nam quia.

Career Advancement Opportunities

August 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Morgan Stanley 08 97.8%
  • Goldman Sachs 02 97.2%

Overall Employee Satisfaction

August 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.3%
  • Banco Santander 02 97.8%
  • BMO Capital Markets 12 97.2%

Professional Growth Opportunities

August 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.8%
  • JPMorgan 01 97.2%

Total Avg Compensation

August 2026 Investment Banking

  • Vice President (16) $429
  • Associates (48) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (25) $178
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (83) $151
  • Intern/Summer Analyst (75) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
kanon's picture
kanon
99.0
4
Secyh62's picture
Secyh62
99.0
5
CompBanker's picture
CompBanker
98.9
6
GameTheory's picture
GameTheory
98.9
7
dosk17's picture
dosk17
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
DrApeman's picture
DrApeman
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”